DayFR Euro

US markets expected to be in the green before PMIs – 12/16/2024 at 3:02 p.m.

(AOF) – American stock markets are expected to be in the green. Investors’ attention will focus on the publication of the PMIs, before the Fed’s decision on Wednesday, which should mark a further rate cut. The Bank of England and the Bank of Japan will also deliver their verdict during this week. In terms of values, Tesla should start sharply higher after analyst Dan Ives predicted a bright future for it under the Trump administration. A few minutes before the first exchanges, futures on the S&P 500 and on the Nasdaq gained 0.26% and 0.45% respectively.

Friday on Wall Street

American stock markets closed without a clear direction during the last session of the week. Investors will learn the Fed’s monetary policy decision on December 17 and 18, which should result in a further rate cut. On the stock side, Broadcom exceeded the $1,000 billion mark in market capitalization during the session, after a strong fourth quarter and strong demand for its AI-related products. The Dow Jones fell 0.20% to 43,828 points while the Nasdaq rose 0.12% to 19,926 points.

Macroeconomic figures

In the United States, purchasing managers’ indices for the manufacturing and services sectors in December will be published at 3:45 p.m.

Values ​​to follow

Honeywell

Honeywell announced that its board of directors is continuing the comprehensive evaluation of its business portfolio launched earlier this year by its chairman and CEO, Vimal Kapur, “to explore additional strategic solutions to generate value for shareholders. The group is studying the potential separation of its aerospace activities. Since December 2023, Honeywell has announced a number of strategic actions “aimed at driving organic growth and simplifying its portfolio following the realignment of its business segments.”

Merck

Merck today announced that Keytruda, was approved by the National Medical Products Administration (NMPA) in China in combination with platinum-containing chemotherapy as neoadjuvant therapy and then continued as monotherapy as adjuvant therapy after surgery for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC). This approval marks the fourth indication for Keytruda against lung cancer in China.

Tesla

Tesla is expected to rise in pre-market on Wall Street after famous analyst Dan Ives (Wedbush) announced on X that he was raising his price target to $515. According to him, a new Trump administration will be a “total game changer” for the manufacturer in the years to come. The analyst estimates that Tesla could reach a market capitalization of $2 trillion by the end of 2025, up from $1.4 trillion today, “as its autonomous vehicle vision begins to take shape.”

Business

-

Related News :